Seek Returns

Viatris (VTRS) Stock Analysis

This is a peer-relative look at Viatris (VTRS): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Viatris (VTRS)
Profile ItemVTRS
NameViatris Inc.
Country/RegionUnited States
GICS SectorHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
GICS Sub-IndustryPharmaceuticals
Market Capitalization22.83 billion USD
CurrencyUSD
ExchangeNasdaq
Listing DateMarch 17, 1980
Security TypeCommon Stock

Price Performance

Cumulative Growth

VTRS
GSPC
Loading price history…
Viatris (VTRS) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Viatris (VTRS) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Viatris (VTRS) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
Total Return (1Y)108.98%24.62%
Total Return (3Y, Annualized)36.75%20.37%
Total Return (5Y, Annualized)11.59%-4.02%

Risk Profile

Drawdown History

VTRS
GSPC
Loading price history…
Viatris (VTRS) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Viatris (VTRS) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
Volatility (1Y, Annualized)32.53%66.36%
Beta (5Y)0.860.93
Max Drawdown (5Y)-45.69%-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. VTRS is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
Sharpe Ratio (1Y)3.220.36
Sortino Ratio (1Y)5.630.58

Profitability

ROE (TTM)

Viatris (VTRS) has negative ROE of -4.21%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Group distribution
Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Largest peers
LLY
86.02%
NVS
24.33%
AZN
22.57%
JNJ
20.02%
MRK
5.06%
VTRS
-4.21%
ABBV
--
Loading chart…
Where Viatris (VTRS) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Viatris (VTRS) has negative net margin of -4.13%. The trailing period ended in a net loss, so the bottom-line conversion read is a warning rather than a profitability strength.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Group distribution
Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Largest peers
LLY
31.90%
AZN
17.68%
NVS
17.49%
JNJ
16.20%
ABBV
15.67%
MRK
3.64%
VTRS
-4.13%
Loading chart…
Where Viatris (VTRS) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Viatris (VTRS) turns 13.85% of revenue into operating profit, roughly in line with the peer group’s normal operating margin range. Its core cost structure looks typical for the industry.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Group distribution
Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Largest peers
LLY
53.66%
ABBV
39.59%
MRK
35.22%
NVS
34.27%
AZN
29.57%
JNJ
25.74%
VTRS
13.85%
Loading chart…
Where Viatris (VTRS) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
ROE (TTM)-4.21%-26.66%
ROA (TTM)2.91%-12.50%
Net Margin (TTM)-4.13%0.00%
Operating Margin (TTM)13.85%0.00%
Gross Margin (TTM)41.13%37.87%

Growth

Revenue Growth

Viatris (VTRS) grew revenue -2.98%, in the lower peer quartile. The top line is expanding more slowly than at most peers, which can reflect softer demand, lost share, or weaker pricing.

Loading chart…
Viatris (VTRS): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

No usable EPS growth is available for Viatris (VTRS) this period, so the earnings-momentum read is skipped.

Loading chart…
Viatris (VTRS) doesn't report EPS Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

Growth Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
Revenue Growth (YoY)-2.98%11.45%
Revenue Growth (3Y CAGR)-4.20%9.94%
EPS Growth (YoY)--4.28%
EPS Growth (3Y CAGR)--4.17%

Financial Strength

Current Ratio (MRQ)

Viatris (VTRS) has current ratio of 1.55, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Group distribution
Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Largest peers
VTRS
1.55
LLY
1.39
MRK
1.35
JNJ
1.02
AZN
1.01
NVS
0.88
ABBV
0.87
Loading chart…
Where Viatris (VTRS) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Viatris (VTRS) has debt-to-equity ratio of 0.99, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Group distribution
Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Largest peers
NVS
1.29
LLY
1.23
MRK
1.20
VTRS
0.99
AZN
0.66
JNJ
0.55
ABBV
--
Loading chart…
Where Viatris (VTRS) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
Current Ratio (MRQ)1.555.52
Debt / Equity (MRQ)0.990.15
Net Debt / EBITDA2.641.08

Dividends

Dividend Yield (TTM)

Viatris (VTRS) has dividend yield of 2.53%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

Group distribution
VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
NVS
2.88%
VTRS
2.53%
ABBV
2.40%
MRK
2.29%
JNJ
1.94%
AZN
1.73%
LLY
0.49%
Loading chart…
Where Viatris (VTRS) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Viatris (VTRS) has payout ratio of 960.00%, meaning dividends exceeded current-period earnings. The gap would need to be covered by cash, retained earnings, financing, or other sources, so earnings alone do not support the payout.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

Group distribution
VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
VTRS
960.00%
MRK
343.43%
ABBV
117.35%
NVS
90.46%
JNJ
80.12%
AZN
45.38%
LLY
21.71%
Loading chart…
Where Viatris (VTRS) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
Dividend Yield (TTM)2.53%0.00%
Dividend Payout Ratio (TTM)960.00%0.00%

Valuation

P/E Ratio (TTM)

No usable P/E ratio is available for Viatris (VTRS) this period, so the trailing-earnings valuation read is skipped.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Group distribution
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Largest peers
MRK
148.21
ABBV
50.05
LLY
43.95
JNJ
41.92
NVS
31.02
AZN
26.37
VTRS
--
Loading chart…
Viatris (VTRS) doesn’t report P/E ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Viatris (VTRS) trades at 1.55 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Group distribution
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Largest peers
LLY
13.95
ABBV
7.80
JNJ
6.69
MRK
5.37
NVS
5.35
AZN
4.63
VTRS
1.55
Loading chart…
Where Viatris (VTRS) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Viatris (VTRS) trades at 1.67 on P/B ratio, in the lower book-value quartile for its industry. Investors are paying less for the balance-sheet equity than they pay for most peers, with returns on that equity still central to the read.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Group distribution
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Largest peers
LLY
29.96
NVS
8.25
JNJ
8.16
MRK
8.06
AZN
5.59
VTRS
1.67
ABBV
-112.34
Loading chart…
Where Viatris (VTRS) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Viatris (VTRS) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: VTRSIndustry group median
P/E Ratio (TTM)--26.69
P/S Ratio (TTM)1.557.30
P/B Ratio (MRQ)1.673.25
Free Cash Flow Yield (TTM)13.84%-1.66%